Comunicati Stampa
Salute e Benessere

Mölnlycke® Health Care and Transdiagen announce research collaboration to drive innovation in wound care

James Harding, CEO, Transdiagen added "We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG's novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds." James Harding, CEO, Transdiagen added "We are thrilled to be...
GOTHENBURG, Sweden, (informazione.it - comunicati stampa - salute e benessere)

James Harding , CEO, Transdiagen added "We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG's novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds."

The collaboration will be initiated shortly. 

For more information, please contact:

Global Communications Director Wound Care
Email: jennifer.doak@molnlycke.com
Phone: +1 678 206 6179

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/molnlycke/r/molnlycke--health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-,c4056056

The following files are available for download:

 

View original content: https://www.prnewswire.co.uk/news-releases/molnlycke-health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-care-302286130.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili